Kaamar Azijli

563 total citations
13 papers, 465 citations indexed

About

Kaamar Azijli is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Kaamar Azijli has authored 13 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Kaamar Azijli's work include Cell death mechanisms and regulation (7 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Renal cell carcinoma treatment (2 papers). Kaamar Azijli is often cited by papers focused on Cell death mechanisms and regulation (7 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Renal cell carcinoma treatment (2 papers). Kaamar Azijli collaborates with scholars based in Netherlands, Japan and Italy. Kaamar Azijli's co-authors include Godefridus J. Peters, Frank A.E. Kruyt, Steven de Jong, Alfons J.M. van den Eertwegh, Ellen Stelloo, Kristy J. Gotink, Henk M.W. Verheul, Henk Dekker, Saravanan Yuvaraj and Thomas Würdinger and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Journal of Cell Science.

In The Last Decade

Kaamar Azijli

12 papers receiving 464 citations

Peers

Kaamar Azijli
Renle Du China
Na Qiao United States
Licai He China
Saketh S. Dinavahi United States
Kaamar Azijli
Citations per year, relative to Kaamar Azijli Kaamar Azijli (= 1×) peers Tzu-Tang Wei

Countries citing papers authored by Kaamar Azijli

Since Specialization
Citations

This map shows the geographic impact of Kaamar Azijli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaamar Azijli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaamar Azijli more than expected).

Fields of papers citing papers by Kaamar Azijli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaamar Azijli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaamar Azijli. The network helps show where Kaamar Azijli may publish in the future.

Co-authorship network of co-authors of Kaamar Azijli

This figure shows the co-authorship network connecting the top 25 collaborators of Kaamar Azijli. A scholar is included among the top collaborators of Kaamar Azijli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaamar Azijli. Kaamar Azijli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Azijli, Kaamar, Geng Xu, Shiv Pillai, et al.. (2025). HSP90 inhibition reverses resistance to TRAIL-induced apoptosis in non-small cell lung cancer cells. SHILAP Revista de lepidopterología. 2(3).
2.
Schuurbiers, Olga C.J., et al.. (2024). 1234P Stage migration in resectable NSCLC. Annals of Oncology. 35. S791–S791. 1 indexed citations
3.
Labots, Mariëtte, Kristy J. Gotink, Henk Dekker, et al.. (2016). Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer. Experimental & Molecular Medicine. 48(12). e279–e279. 21 indexed citations
4.
Azijli, Kaamar, Kristy J. Gotink, & Henk M.W. Verheul. (2016). The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer. SHILAP Revista de lepidopterología. 2(4). 195–203. 23 indexed citations
5.
Gotink, Kristy J., Maria Rovithi, Richard R. de Haas, et al.. (2015). Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cellular Oncology. 38(2). 119–129. 46 indexed citations
6.
Azijli, Kaamar, Masakazu Fukushima, Steven de Jong, et al.. (2014). The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells. Cancer Chemotherapy and Pharmacology. 73(6). 1273–1283. 11 indexed citations
7.
Azijli, Kaamar, Ellen Stelloo, Godefridus J. Peters, & Alfons J.M. van den Eertwegh. (2014). New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.. PubMed. 34(4). 1493–505. 73 indexed citations
8.
Azijli, Kaamar, Saravanan Yuvaraj, Koen D. Flach, et al.. (2013). MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. APOPTOSIS. 18(7). 851–860. 38 indexed citations
9.
Azijli, Kaamar, et al.. (2013). Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death and Differentiation. 20(7). 858–868. 145 indexed citations
10.
Azijli, Kaamar, Saravanan Yuvaraj, Maikel P. Peppelenbosch, et al.. (2012). Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3 dependent invasion in resistant non-small cell lung cancer cells. Journal of Cell Science. 125(Pt 19). 4651–61. 59 indexed citations
11.
Azijli, Kaamar, Jos Joore, Saravanan Yuvaraj, et al.. (2012). TRAIL-induced pro- and anti-apoptotic kinase activation in Non small cell lung cancer cells. Data Archiving and Networked Services (DANS). 23. 35–36. 18 indexed citations
12.
Bijnsdorp, Irene V., Kaamar Azijli, Erwin E. W. Jansen, et al.. (2010). Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells. Biochemical Pharmacology. 80(6). 786–792. 29 indexed citations
13.
Azijli, Kaamar, Henk Dekker, Jos Joore, et al.. (2010). Abstract 1261: TRAIL-induced pro- and antiapoptotic kinase activation in non-small cell lung cancer cells. Cancer Research. 70(8_Supplement). 1261–1261. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026